You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Anticoagulation Management and Vascular Protection

The non-vitamin K antagonist oral anticoagulants (NOACs) have the potential to change the way thromboembolic disorders are treated. The Anticoagulation Management section of this site will highlight clinical data updates in settings of atrial fibrillation and venous thromboembolism where the NOACs are now widely used and discuss application of the latest data in patient care.

NOACs are also being investigated in other disorders, including coronary and peripheral artery disease (CAD/PAD), heart failure, and others. The Vascular Protection section of the site will explore the emerging clinical data for NOACs and discuss new paradigms in thrombotic protection and potential implications for clinical care.

View programs for: Anticoagulation Management Vascular Protection

Supported by

Bayer AG

Anticoagulation Management

Thrombosis-TV Season 7

Thrombosis-TV Season 6

AF-related stroke

VTE

Steering Committee - Anticoagulation Management

Keith A.A. Fox, MBChB, FRCP, FMedSci

Steering Committee Chair

Professor of Cardiology
University of Edinburgh
Edinburgh, United Kingdom

A. John Camm, MD

Professor
St. George's University of London
London, United Kingdom

Craig I. Coleman, PharmD

Professor
University of Connecticut
Storrs, Connecticut, United States

Dominique Farge-Bancel, MD

Professor of Internal Medicine and Vascular Disease
H�pital Saint-Louis, AP-HP
Paris University France
McGill University
Montreal, Quebec, Canada

Alok A. Khorana, MD

Alok A. Khorana, MD

Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Sondra and Stephen Hardis Chair in Oncology Research
Vice Chair (Clinical Services)
Director
GI Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio, United States

Christian T. Ruff, MD, MPH

Christian T. Ruff, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Director of General Cardiology
Cardiovascular Division
TIMI Study Group
Brigham and Women's Hospital
Boston, Massachusetts, United States

Peter Verhamme, MD, PhD

Peter Verhamme, MD, PhD

Professor
University of Leuven
Leuven, Belgium

Vascular Protection

CAD/PAD

Steering Committee - Vascular Protection

Keith A.A. Fox, MBChB, FRCP, FMedSci

Keith A.A. Fox, MBChB, FRCP, FMedSci

Steering Committee Chair

Professor of Cardiology
University of Edinburgh
Edinburgh, United Kingdom

Victor Aboyans, MD, PhD

Victor Aboyans, MD, PhD

Professor
Head of Department of Cardiology
Dupuytren University Hospital
Limoges, France

Deepak Bhatt, MD, MPH

Deepak L. Bhatt, MD, MPH

Professor of Medicine
Harvard Medical School
Executive Director, Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart & Vascular Center
Boston, Massachusetts, United States

John W.A. Eikelboom, MBBS, MSc

John W.A. Eikelboom, MBBS, MSc

Professor
McMaster University
Hamilton, Ontario, Canada

Manesh R. Patel, MD<

Manesh R. Patel, MD

Professor of Medicine
Duke University Medical Center
Durham, North Carolina, United States

Robert C. Welsh, MD, FRCPC<

Robert C. Welsh, MD, FRCPC

Professor of Medicine
University of Alberta in Edmonton
Director of Cardiac Catheterization and Interventional Cardiology
Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada

Related Resources

Downloadable Slide Kit

Navigating PAD: From Early Recognition to Treatment

PAD is under-recognized and is associated with a high burden of disease and complications. Review the latest information, including guideline recommendations for the treatment of PAD.

Download

Latest Perspectives in Antithrombotic Therapy in CAD and PAD

Despite optimal therapy, patients with prior ischemic events and perceived stable disease remain at risk for future vascular events. Review risk factors and current and future antithrombotic considerations for CAD and PAD.

Download

A Review of the Global Burden and Prevention of Thrombosis

Review the global burden of thrombosis, strategies for prevention, and the role of antithrombotics in peripheral artery disease, venous thromboembolism, and heart failure.

Download

A Review of Non-vitamin K Antagonist Oral Anticoagulants

Stroke Prevention in Atrial Fibrillation

Download

A Review of Non-vitamin K Antagonist Oral Anticoagulants

Venous Thromboembolism

Download

Clinical Reference Articles

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. 

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH 

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes 

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) 

Patient Simulation in Stroke Prevention in AF: Improving the Use of Guideline-Directed Care 

Improving Management of Acute Hypertension: Success of Online CME 

Patient Simulation in CAD: Improving Performance of Cardiologists Through Online CME 

DOACs and Cancer-Associated Thrombosis: Effect of Online CME on Knowledge and Confidence of Physicians 

Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer 

Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease? 

XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. 

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.  

Rivaroxaban with or without aspirin in stable cardiovascular disease  

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial  

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial  

Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation  

Idarucizumab for dabigatran reversal - full cohort analysis  

Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism  

Rivaroxaban or aspirin for extended treatment of venous thromboembolism  

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial  

Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy  

Use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants (NOACs) before stroke  

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1  

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2  

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation  

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial  

Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism  

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)  

Rivaroxaban versus heparin bridging to warfarin therapy: impact on hospital length of stay and treatment costs for low-risk patients with pulmonary embolism  

Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH  

Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting  

Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)

Trends in the management and outcomes of acute pulmonary embolism. Analysis from the RIETE registry